Evidence mapPaperPMID 40176064Full record

ArticleCardiovascular diabetology2025

Lipidomic analysis reveals metabolism alteration associated with subclinical carotid atherosclerosis in type 2 diabetes.

Maria Barranco-Altirriba, Joana Rossell, Núria Alonso, Ralf J M Weber, Emilio Ortega, Gavin R Lloyd, Marta Hernandez, Oscar Yanes, Jordi Capellades, Catherine Winder and 7 more

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maria Barranco-AltirribaDepartment of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Joana RossellDepartment of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Núria AlonsoCIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.
Ralf J M WeberSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Emilio OrtegaDepartment of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, 08036, Barcelona, Spain.
Gavin R LloydSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Marta HernandezDepartment of Endocrinology and Nutrition, Hospital Universitari Arnau de Vilanova i Institut d'investigació biomèdica de Lleida (IRBLleida), Lleida, Spain.
Oscar YanesCIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.
Jordi CapelladesCIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.
Catherine WinderSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Alexandra JunzaCIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.
Mireia FalgueraInstitute for Biomedical Research Dr. Pifarré Foundation IRB Lleida, University of Lleida and Primary Health Care Centre Tàrrega, Gerència d'Atenció Primaria, Institut Català de la Salut, Lleida, Spain.
Josep Franch-NadalCIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.
Warwick B DunnSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Alexandre Perera-LlunaB2SLab, Department of Systems Engineering, Automatics, and Industrial Informatics, Universitat Politècnica de Catalunya, Barcelona, Spain.
Esmeralda CastelblancoDivision of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA. esmeralda@wustl.edu.
Didac MauricioDepartment of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. didacmauricio@gmail.com.

Funding

Agencia Estatal de Investigación PID2021-122952OB-I00Fundació la Marató de TV3 303/C/2016Instituto de Salud Carlos III AC22/00035Instituto de Salud Carlos III PI15/0625Instituto de Salud Carlos III PI17/01362
6 · The paper itself

Abstract

backgroundDisruption of lipid metabolism contributes to increased cardiovascular risk in diabetes.

methodsWe evaluated the associations between serum lipidomic profile and subclinical carotid atherosclerosis (SCA) in type 1 (T1D) and type 2 (T2D) diabetes, and in subjects without diabetes (controls) in a cross-sectional study. All subjects underwent a lipidomic analysis using ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometry, carotid ultrasound (mode B) to assess SCA, and clinical assessment. Multiple linear regression models were used to assess the association between features and the presence and burden of SCA in subjects with T1D, T2D, and controls separately. Additionally, multiple linear regression models with interaction terms were employed to determine features significantly associated with SCA within risk groups, including smoking habit, hypertension, dyslipidaemia, antiplatelet use and sex. Depending on the population under study, different confounding factors were considered and adjusted for, including sample origin, sex, age, hypertension, dyslipidaemia, body mass index, waist circumference, glycated haemoglobin, glucose levels, smoking habit, diabetes duration, antiplatelet use, and alanine aminotransferase levels.

resultsA total of 513 subjects (151 T1D, 155 T2D, and 207 non-diabetic control) were included, in whom the percentage with SCA was 48.3%, 49.7%, and 46.9%, respectively. A total of 27 unique lipid species were associated with SCA in subjects with T2D, in former/current smokers with T2D, and in individuals with T2D without dyslipidaemia. Phosphatidylcholines and diacylglycerols were the main SCA-associated lipidic classes. Ten different species of phosphatidylcholines were up-regulated, while 4 phosphatidylcholines containing polyunsaturated fatty acids were down-regulated. One diacylglycerol was down-regulated, while the other 3 were positively associated with SCA in individuals with T2D without dyslipidaemia. We discovered several features significantly associated with SCA in individuals with T1D, but only one sterol could be partially annotated.

conclusionsWe revealed a significant disruption of lipid metabolism associated with SCA in subjects with T2D, and a larger SCA-associated disruption in former/current smokers with T2D and individuals with T2D who do not undergo lipid-lowering treatment.

Indexed as

Carotid Artery DiseasesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2DyslipidemiasLipid MetabolismLipidomicsLipidsAdultAgedAsymptomatic DiseasesBiomarkersCase-Control StudiesCross-Sectional StudiesFemaleHumansMaleBiomarkersLipidsLipidomic profileSmoking habitSubclinical carotid atherosclerosisType 1 diabetesType 2 diabetes

Identifiers

PMID40176064
PMCPMC11967040

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.